Spatiotemporal Expression Pattern of Gadd45g Signaling Pathway Components in the Mouse Uterus Following Hormonal Steroid Treatments

Yvan Labrie, Karine Plourde, Johanne Ouellet, Geneviève Ouellette, Céline Martel, Fernand Labrie, Georges Pelletier and Francine Durocher*

Key Words: Uterus; Ovariectomized mice; Estrogens; Androgens; in situ hybridization; Gadd45g

Introduction

The uterus is a hormone-dependent organ under the control of estrogens, progestins and androgens. The actions of estradiol (E2) and progesterone on uterine physiology are well documented, while active androgens such as testosterone and dihydrotestosterone (DHT) are now also recognized to exert an important role to appropriately maintain the cyclical changes of the endometrium.

Based on our previous observations that DHT modulates GADD45g and the expression of specific cell cycle genes, the aim of this study was to identify the specific uterine cell types in which these cell cycle genes are modulated by hormonal steroids.

Using in situ hybridization and quantitative RT-PCR (QRT-PCR), the localization and measurement of mRNA expression of key cell cycle genes responding to E2 and DHT were performed in the uterus of ovariectomized mice. Interestingly, in situ hybridization experiments demonstrate that Gadd45g mRNA is detected early and strongly in stromal cells only, indicating that the early cell cycle arrest induced by DHT and E2 in the mouse uterus occurs in this compartment. On the other hand, the cell cycle stimulation represented by the late increase of Ccnb1, Cdc2a and Cdc25c gene expression is located exclusively in the glandular and luminal epithelial cells. QRT-PCR experiments confirm the regulation of mRNA expression observed following in situ hybridization. Surprisingly, both hormones appear to trigger effects in the same direction on cell cycle progression, with androgens inducing a lower modulation of gene expression levels. Additional experiments using the human uterine Ishikawa cell line confirmed the implication of the estrogen receptor in the GADD45g up-regulation following treatment with E2 while the regulation triggered by DHT is less clear. These observations illustrate clearly the stroma-epithelium interactions, which finely regulate the uterine physiology via paracrine mechanisms. Additional investigations are definitely needed to determine the exact role played by androgens in mouse uterine growth and differentiation.

Abstract

The uterus is a hormone-dependent organ under the control of estrogens, progestins and androgens. The actions of estradiol (E2) and progesterone on uterine physiology are well documented, while active androgens such as testosterone and dihydrotestosterone (DHT) are now also recognized to exert an important role to appropriately maintain the cyclical changes of the endometrium [1-6].

In both men and women, androgens are much more abundant than estrogens in terms of circulating steroids. In recent years, increasing evidence supports the use of androgens as hormone replacement therapy (HRT) in postmenopausal women to significantly improve their quality of life. Indeed, menopausal decline in androgens triggers side-effects influencing libido, vasomotor symptoms, mood, well-being, bone structure and muscle mass [7,8]. Moreover, the greater risk of breast cancer, deleterious effects on cardiovascular systems and other negative effects attributed to progestins [9,10] reinforces the use of a combination of estrogens and androgens as HRT in menopausal women [11-13]. In the mouse, while the estrogenic stimulation of proliferation of uterine epithelial and stromal cell growth and differentiation is well documented [14-20] the observation that DHT also exerts modulatory effects on these cells is known but not elucidated [1-4].

The signal sent by these hormones is transduced by their respective steroid receptors located in the different uterine compartments. Excluding some splicing variants, two major estrogen receptor (ER) forms, namely ERα and ERβ are expressed in both the epithelial and stromal cells of the rodent uterus [21-27]. Although ERβ is detected to a lower level and exclusively in the late phase of gestation, both forms are expressed throughout gestational development in a temporalspecific manner [5]. As for the androgen receptor (AR) it is expressed in both types of epithelial cells (glandular and luminal), in stromal and smooth muscle cells of the rat and mouse [27-29], and in the human uterus [30].

Few hypotheses have been suggested so far to explain the inhibitory action of androgens on the proliferative effect of estrogens, such as: 1) androgens can inhibit estrogenic effects by activating AR [31]; 2) the ligand-activated AR can interact with ERα and thus lowers its transcriptional activity [32] and; 3) androgens induce the down-regulation of ERα particularly in stromal and myometrial cells [33]. On the other hand it has been demonstrated that androgens can alter uterine weight and its morphology, and that AR induces an estrogen-like gene expression response which is required for growth and differentiation of stromal and epithelial cells [34]. Moreover,

*Corresponding author: Francine Durocher, CREMOGH, CHUL Research Centre, Department of Molecular Medicine, Laval University, 2705 Laurier Blvd T2-53, Quebec, G1V 4G2, Canada, Tel: 418-656-4141, ext: 48508; Fax: 418-654-2761; E-mail: Francine.Durocher@crchul.ulaval.ca

Received November 20, 2011; Accepted February 15, 2012; Published February 17, 2012

Citation: Labrie Y, Plourde K, Ouellet J, Ouellette G, Martel C, et al. (2012) Spatiotemporal Expression Pattern of Gadd45g Signaling Pathway Components in the Mouse Uterus Following Hormonal Steroid Treatments. Endocrinol Metab Syndrome S4:005. doi:10.4172/2161-1017.S4-005

Copyright: © 2012 Labrie Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
critical interactions between stromal and epithelial cells have been demonstrated to mediate the hormone effects on epithelial cells [35].

The major uterine cancer, referred to as endometrial cancer, first develops in the glandular cells of the lining. Later this cancer may spread in stromal cells and ultimately into myometrium and cervix. On the other hand sarcomas, representing about 5% of uterine cancers, arise in myometrial cells, grow rapidly and may also reach the endometrium [36].

In a previous study we have demonstrated a significant up-regulation of expression of Gadd45g and other key cell cycle genes (Rad51, Cdc2a, Ccnb1 and Cdc25c) following an androgenic treatment [4], and all these genes interact with each other in a common pathway. Gadd45g expression, like other Gadd45 family members (a and b), is induced in response to multiple environmental and physiological stress [37]. However, each member of the family likely has a unique function, Gadd45g being mainly induced as a primary response to IL-2 and IL-6 [38].

Despite the well-known inhibitory effect of DHT on estrogen-induced uterine epithelial cell proliferation, the mechanism by which a single DHT treatment exerts a residual estrogen-like action on cell proliferation is unknown. Therefore, based on our recent investigation demonstrating a stimulation of the cell-cycle by DHT on mouse uterine cells [4], we undertook in situ and QRT-PCR experiments to assess the expression of key cell cycle components and discriminate their localization following estrogenic and androgenic treatments in the mouse uterus.

Materials and Methods

Animals and treatment

Ten to eleven week-old female C57BL/6 mice were received from Charles River (St-Constant, Canada) and were allowed to acclimate for 4 weeks. The animals were housed individually in an environment-controlled room (temperature: 22 ± 3°C; humidity: 50 ± 20%; 12-h light-12-h dark cycles, lights on at 07:15h). The mice had free access to tap water and a certified rodent feed (Lab Diet 5002 (pellet), Ralston Purina, St Louis, MO). The experiment was conducted in an animal facility approved by the Canadian Council on Animal Care (CCAC) and the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). The study was performed in accordance with the CCAC Guide for Care and Use of Experimental Animals. Animals, weighing between 20 to 27g (mean 23.3g), were randomized according to the CCAC Guide for Care and Use of Experimental Animals [37]. Each member of the family likely has a unique function, Gadd45g being mainly induced as a primary response to IL-2 and IL-6 [38].

Despite the well-known inhibitory effect of DHT on estrogen-induced uterine epithelial cell proliferation, the mechanism by which a single DHT treatment exerts a residual estrogen-like action on cell proliferation is unknown. Therefore, based on our recent investigation demonstrating a stimulation of the cell-cycle by DHT on mouse uterine cells [4], we undertook in situ and QRT-PCR experiments to assess the expression of key cell cycle components and discriminate their localization following estrogenic and androgenic treatments in the mouse uterus.

In situ hybridization

Frozen sections (10 μm thick) were serially cut and mounted onto gelatin- and poly-L-lysine-coated slides. Recombinant plasmid PCR® 2.1 (Invitrogen, Burlington, Ont, Canada) containing Mus musculus Gadd45g (485 bp, position 123-607 of NM_001817), Rad51 (821 bp, position 284-1104 of NM_011234), Ccnb1 (827 bp, position 428-1254 of NM_172301), Cdc2a (739 bp, position 207-945 of NM_007659.3) or Cdc25c (810 bp, position 674-1483 of NM_009860) fragments were used as DNA template for cRNA probe synthesis. These cDNA fragments were previously obtained by amplification using primer-specific polymerase chain reaction. In situ hybridization with antisense and sense 3′-labeled cRNA probes was performed as previously described [40]. After hybridization, tissue sections were dehydrated and coated with liquid photographic emulsion (Kodak-NTB2; diluted 1:1 with water), and following 30–45 days of exposure, sections were processed and counterstained with haematoxylin.

Chemicals and cell culture experiments

E2 was obtained from Steraloids (Wilton, NH) while DHT was generously provided by Dr André Tchernof (Quebec, Canada). All media and supplements for cell culture were from Wisent Inc. (St-Bravo, QC), except for DMEM without phenol red, which was from Gibco (Burlington, ON). Fulvestrant and Casodex were purchased from Sigma Chemical Co (St. Louis, MO).

The human Ishikawa cell line derived from a well-differentiated endometrial adenocarcinoma [41] was kindly provided by Dr.
Chantal Guillomette (CHUQ Research Centre, Quebec, Canada). The Ishikawa cells were routinely maintained in DMEM containing 10% (v/v) FBS and supplemented with 100 units/ml penicillin, 100 µg/ml streptomycin, 1% nonessential amino acids, 2 mM glutamine, and 1 mM sodium pyruvate. Cells were plated in Falcon T75 flasks at a density of 1.5 X 10^5 cells at 37°C 5% CO2.

Twenty-four hours before the start of the experiment, Ishikawa cells were cultured to 60% confluency in a DMEM phenol red-free, all supplements mentioned above, and 0.25% FBS treated with dextran-coated charcoal to remove endogenous steroids. The day of the experiment, medium was replaced with fresh DMEM 0.25% FBS-charcoal containing the indicated concentrations of compounds (DHT: 1nM, Estradiol: 10nM, Fulvestrant: 1µM) in a final volume of 12 ml. Casodex at 1 µM was incubated with Ishikawa cells 1 h before the addition of androgens/estrogens wherever appropriate. It should be noted that doses of hormones or anti-hormones have been determined based on those commonly used in the literature. Cells were incubated at 37°C for 24 h, and half of the cells from a flask were homogenized in TRI Reagent solution (Ambion, Austin, TX) for RNA extraction.

**Results**

To further explore the mechanisms of the anti- and pro-proliferative effects of E2 and DHT on the mouse uterus, *in situ* hybridization and gene expression analyses (*QRT*-PCR) were performed on uterine tissue from the OVX mouse uterus treated either with E2 or DHT during 3h, 12h or 24h, using ^35^S-labeled probes for Gadd45g (anti-proliferative effect) as well as for Rad51 (DNA repair gene allowing S-phase progression), Cdc2a, Ccnb1 and Cdc25c genes (pro-proliferative effect).

Regarding Gadd45g, a strong labeling was detected in the stromal cells of endometrial tissue, with a transient peak of signal intensity observed at a 3h time-interval with either E2 or DHT. Following treatment with E2, the labelling intensity declines at 12h (4-fold), and then decreases to the levels present in the control group at 24h (Figure 1). However, when DHT is administered, with the exception of the peak of expression at 3h, timepoints at 12h or 24 h do not reveal any significant increase in Gadd45g expression (Figure 2). DHT thus seems to exert a shorter effect on Gadd45g expression than E2. A weak staining is also observed in myometrial cells (data not shown), but no Gadd45g mRNA expression is observed in glandular and luminal epithelial cells for both hormones. The *QRT*-PCR experiments performed also support a peak of expression observed at 3h following both hormonal treatments. As illustrated in Figures 1 and 2, no significant autoradiographic reaction was observed following hybridization with the sense probe, which corresponds to the peak of expression, i.e. timepoint at 3h. Furthermore, as demonstrated by *QRT*-PCR experiments, E2 induces a much higher (30-fold) Gadd45g gene expression at 3h when compared to the control group, and over a longer time-interval (at 3h and 12h) than that observed following a DHT treatment (5-fold at 3h only).

Although non-significant, Rad51 expression showed a trend of up-regulation at 12h and 24h for both hormones (< 2-fold) (Figure 3A), and this expression is mainly detected in luminal and glandular epithelial cells (data not shown). Again Rad51 mRNA quantification is in agreement with the *in situ* hybridization experiments described above.

As for Ccnb1, Cdc2a and Cdc25c, they all interact with each other to control the G2/M phase transition. As observed for Rad51, *in situ* hybridization reveals that the increased expression of Ccnb1 (data not shown), Cdc2a (Figure 4 and Figure 5) and Cdc25c (data not shown) occur exclusively in the luminal and glandular epithelial cells (at 12h and/or 24h) while no significant change or no signal of mRNA expression is detected in stromal cells.

While Cdc2a mRNA expression increases gradually at 12h and 24h following a treatment with E2 (but to a lower level of induction with DHT) (Figures 4 and 5), the Cdc25c gene showed a clear induction of expression at 24h (E2: 3.2-fold), and also to a lower extent for DHT (2.4-fold) (Figure 3C). As for Ccnb1, E2 triggers a significant up-regulation of mRNA expression at 24h (2.3-fold), while only a modest increase is observed following an androgenic treatment (1.6-fold) (Figure 3B). Again, for all the genes tested involved in the promotion of the cell cycle (G2/M transition), hybridization with the radio labeled sense probe generated only a light, uniform background.

Specific histological changes are also triggered by both hormone treatments. As observed at the 12h and 24h time intervals, E2 administration induced an increase in the surface of endometrial components and muscle layer. The stroma cells appeared larger and less densely packed than those observed in untreated OVX animals (Figure 4). The epithelial cell height was also increased following E2...
Treatment (Figure 4). Similar changes, although less striking was also observed in DHT-treated animals (Figure 5).

Taken together, our results indicate that for the genes studied, both hormones induce effects in the same direction on cell cycle components expression, although estrogens (E2) exert a much stronger stimulation than androgens (DHT). Regarding the localization of the mRNA expression of these genes, both hormones seem to induce the expression in the same uterine compartments.

To establish whether AR and/or ER mediate the action of estrogens/androgens on GADD45g up-regulation, the ideal model would have been a mouse uterine cell line. However, to our knowledge no such cell line is available; therefore we used the human Ishikawa cell line which is routinely cultured in our laboratory to discriminate the role of both receptors in this regulation. As demonstrated, the expression of the estrogen-responsive gene ALPPL2 is strongly increased by E2 and this up-regulation is strongly but not completely inhibited in the presence of fulvestrant, while the selected androgen-responsive gene AR is significantly increased by E2 only. Given that GADD45g mRNA up-regulation could be linked to an increase of proliferation, we measured the mRNA levels of the proliferation gene PCNA. No significant change of mRNA regulation was observed following the estrogenic or androgenic treatment in Ishikawa cells (data not shown).
Discussion

Based on our previous microarray hybridization analyses indicating that androgens could stimulate the cell cycle progression to a certain level, here using QRT-PCR and in situ hybridization, we undertook a study on the localization as well as the quantification of key cell cycle components mRNA expression in mouse uterine tissue following androgenic (DHT) or estrogenic (E2) treatment.

The importance of the stromal-epithelial interactions has been well demonstrated using the tissue recombinant system, which allowed determining the role of steroid receptors in each tissue compartment. For example, it has been demonstrated that androgens cause embryonic mammary epithelial regression via the AR-positive mesenchyme, which in response to androgens is stimulated to condense around the epithelium, thus triggering epithelial regression [42]. Indeed, the effects of these hormones on female reproductive tract epithelium are mediated totally or in part through the corresponding receptors in stromal cells [43,44].

As observed following an estradiol treatment, androgens administration leads to a significant increase in endometrial and myometrial cross-sections area, which represents a clear trophic effect after 24h [3]. However, it has been demonstrated that E2 and DHT trigger distinct effects on the thickness and morphology of epithelial cells layer as well as on the edematous appearance of stromal cells [3]. Both hormones, particularly E2 after 4h, provoke a major influx of fluid into the uterus, and this increased vascular permeability is in part due to an increased mRNA expression of the vascular endothelial growth factor (VEGF) [18]. Indeed, in our previous studies VEGF mRNA expression was up-regulated by 6.7-fold and 3-fold at 3h following E2 or DHT administration, respectively [4,20], which supports its involvement in the regulation of vascular permeability.

In this study, DHT modulates cell cycle gene expression, although to a lower extent than with E2, and this expression occurs in the same compartments than those observed following E2 administration. Following either treatment with DHT or E2, the proliferative effect, represented by the induction of Ccnb1, Cdc2a and Cdc25c gene expression, is observed in the late phase of treatment (12h and 24h) in both glandular and luminal epithelial cells. This seems to correlate with the release of Gadd45g repression. Indeed, given that the Gadd45g expression increases dramatically during the early period of...
hormonal treatment, and exclusively in stromal cells, this illustrates the importance of the stromal-epithelial compartment interactions, which regulate uterine cell growth and differentiation [35].

The Gadd45g gene product is known to play pivotal roles in G2/M arrest and induction of apoptosis signaling through the dissociation of the cyclinB/Cdc2 complex [45,46]. As both ER and AR are expressed in stromal cells, and given that the early induction of Gadd45g expression (3h) occurred exclusively in this compartment, this suggests a direct receptor-mediated action of both hormones leading to cell cycle arrest. However, previous observations have shown that Gadd45g is an up-regulated androgen-responsive gene with growth inhibitory activity in human prostate cancer cells, showing a rapid and transient dose-dependent stimulation followed by a decreased expression after 48h [47]. Moreover, this study supports that this up-regulation is sensitive to protein synthesis inhibition, suggesting an indirect effect of androgens on Gadd45g promoter. Indeed, E2 and DHT induce a rapid and transient expression of Gadd45 in the breast cancer cell line MCF7 [48] and in human prostate cancer cells [47], respectively, which is in agreement with the results described here.

It has also been suggested that an increased expression of the Gadd45 gene might not be directly linked to hormonal stimulation, but rather be caused by DNA damage induced by the hormone-treatment regimen [49]. In addition, Gadd45g expression has been shown to be induced by DNA damage in both a p53-dependent [50] and -independent [45,51] manner, and up-regulation of this gene could also be modulated by the oxidative stress [52]. Moreover, as it is the case for the expression of the p27 gene which is induced in stromal cells by E2 and TGFβ through paracrine mechanisms, Gadd45g gene expression is also induced by TGFβ, and both gene activation leads to cell cycle arrest, either at G1/S (p27) or G2/M phase (Gadd45g) [53-56]. Therefore one could speculate that the inhibition of cell cycle in both epithelial and glandular cells may be regulated in part via the stromal cells compartment.

Most studies regarding the cell cycle regulation by hormonal steroids mainly investigated genes involved in the G1 phase transition, namely Cyclin D and E as well as CDK inhibitors such as p21 and p27 [53,57]. On the other hand, the G2/M phase progression involves the activity of several cell-cycle regulatory proteins, such as Cyclin B1, Cdc2, Wee1, Cdc25C, and others [58-61]. Indeed, Ccnb1 expression would be stimulated as a consequence of DNA synthesis in rat uterine luminal epithelium rather than a direct response to estradiol treatment [62]. Although not statistically significant, an up-regulation of Ccnb1 gene expression has been reported in endometrial hyperplasia and endometrial cancer [63-66]. Indeed, G2 pathway alterations seem to be a moderately frequent event in endometrial cancer, and are thought to occur during carcinogenesis of the endometrium [64].

Despite the similar regulation and localization of key cell cycle regulators (such as Rad51, Gadd45g, Cdc2a, Cdc25c and Ccnb1) induced by both hormones, the results obtained in this study suggest that they are unlikely the major factors responsible for the residual estrogen-like effect observed on uterine cell proliferation triggered by an androgen treatment. It is likely that DHT regulates the trophic environment and architecture of the rodent uterus through a gene expression program, which is overlapping but distinct from the estrogen response [3]. However, the non-aromatizable androgenic hormone DHT can also be metabolized by 3β-hydroxysteroid dehydrogenase to 3βAdiol which has been shown to bind, although with a much lower affinity than E2, both ERα and ERβ [67]. During profound estrogen deprivation, 3βAdiol has been demonstrated to be estrogenic in the breast and reproductive tissues [68]. Indeed, 3βAdiol can induce the proliferation of breast cancer cells through direct activation of ERα [69]. Moreover, it has been reported that breast cancer cells can become hypersensitive to low concentrations of estrogens (3βAdiol) after long-term estrogen deprivation [70,71]. Thus, the androgen 3βAdiol resulting from DHT conversion could be involved in this residual estrogen-like effect observed in uterine tissues following a single DHT administration in OVX mice.

It was also of interest to determine the individual role of AR and ER in the regulation of GADD45g gene expression. Although the androgenic regulation in rodent and human endometrial cells is known to be different, we treated the only uterine cell line available, namely the Ishikawa cells with steroids and anti-hormones. Indeed, the androgens exert an uterotrophic action in mouse uterus [2-4,70,73] while in human endometrium, androgens are likely to be involved in the differentiation of human endometrial stromal cells into decidual cells as well as in the regulation of endometrial function pertaining to implantation and pregnancy [73]. As described in Figure 6, ER is likely to be involved in this regulation. However we could not confirm...
the implication of AR, given the absence of significant up-regulation following DHT treatment. Indeed, there is no well-established androgen-responsive gene which has been reported in the literature to be significantly modulated by androgens in human uterus. Apparao et al. [74] described the up-regulation of AR proteins in Ishikawa cells following an androgenic treatment of 3-4 days, and Lovey’s group reported a modest positive effect on AR binding activity and expression by Northern blot analysis [75]. However, in the current study we treated Ishikawa cells for 24h given that the increase of our gene of interest, GADD45g, was observed after a treatment of 3 hours in the mouse uterus, which could explain the absence of modulation of AR following DHT treatment. On the other hand, it is well known that estrogens up-regulate AR mRNA and protein expression in the well-differentiated human endometrial adenocarcinoma Ishikawa cell line [76,77]. Therefore, while we can confirm the involvement of ER in the up-regulation of GADD45g mRNA expression, we cannot exclude the participation of AR on the up-regulation observed previously in mouse uterus based exclusively on the results described above in human endometrial cells. In addition as described previously, the increase of GADD45g mRNA levels in Ishikawa cells following an estrogenic treatment of 24h could not be explained by cell proliferation given the absence of significant mRNA regulation of the proliferation gene PCNA. The results described above illustrate clearly that the stroma-epithelium interactions seem to finely regulate the uterine physiology via paracrine mechanisms. Other investigations are however definitely needed to identify additional players involved in the opposite actions (anti- and proliferative) induced by DHT in the presence and/or absence of estrogens, which could then further explain the exact role of androgens in mouse uterine growth and differentiation.

Acknowledgements

We would like to thank the research assistants involved in animal care and treatments for their skillful technical assistance. Also we would like to thank Nathalie Paquet for QRT-PCR experiments.

This work was supported by Genome Canada and Genome Québec for the ATLAS project. F.D. is a recipient of a Chercheur boursier from the Fonds de la Recherche en Santé du Québec, and of a Research Career Award in Health Sciences by CIHR/Rx&D HRF (Health Research Foundation).

References

1. Lerner LJ (1964) Hormone Antagonists: Inhibitors of Specific Activities of Estrogen and Androgen. Recent Prog Horm Res 20: 435-490.
2. Armstrong DT, Moon YS, Leung PC (1976) Uterotrophic effects of testosterone and Sulphate dihydrotestosterone in intact and ovariectomized immature female rats. Biol Reprod 15: 107-114.
3. Nantermet PV, Masarachia P, Gentile MA, Pennypacker B, Xu J, et al. (2005) Androgenic induction of growth and differentiation in the rodent uterus involves the modulation of estrogen-regulated genetic pathways. Endocrinology 146: 564-578.
4. Ivanga M, Labrie Y, Calvo E, Belleau P, Martel C, et al. (2009) Fine temporal analysis of DHT transcriptional modulation of the ATM/Gadd45g signaling pathways in the mouse uterus. Mol Reprod Dev 76: 278-288.
5. Okada A, Sato T, Ohta Y, Iuchi T (2005) Sex steroid hormone receptors in the developing female reproductive tract of laboratory rodents. J Toxicol Sci 30: 75-89.
6. Mertens HJ, Heinemen MJ, Theunissen PH, de Jong FH, Evers JL (2001) Androgen, estrogen and progesterone receptor expression in the human uterus during the menstrual cycle. Eur J Obstet Gynecol Reprod Biol 98: 56-65.
7. Burd ID, Bachmann GA (2001) Androgen replacement in menopause. Curr Womens Health Rep 1: 202-205.
8. Berg G, Gottwall T, Hammar M, Lindgren R (1988) Climacteric symptoms among women aged 60-62 in Linköping, Sweden, in 1986. Maturitas 10: 193-199.
9. Stalhberg C, Pederson AT, Lyng E, Ottesen B (2003) Hormone replacement therapy and risk of breast cancer: the role of progestins. Acta Obstet Gynecol Scand 82: 335-344.
10. Chanson P (2005) [Historical perspective of hormone replacement therapy]. Rev Prat 55: 369-375.
11. Coutinho EM, Teixeira CE, Maltez A, Maia H (2002) Long-term testosterone replacement therapy with slow-release silastic implants. In Advances in gynaecological endocrinology: The proceedings of the plenary sessions of the 8th World Congress of Gynecological Endocrinology, Parthenon Publishing Group, London.
12. Magos AL, Brincat M, O'Dowd T, Wardie PJ, Schlesinger P, et al. (1985) Endometrial and menstrual response to subcutaneous oestradiol and testosterone implants and continuous oral progesterone therapy in post-menopausal women. Maturitas 7: 297-302.
13. Cardozo L, Gibb DM, Tuck SM, Thom MH, Studd JW, et al. (1984) The effects of subcutaneous hormone implants during climacteric. Maturitas 5: 177-194.
14. Huet-Hudson YM, Andrews GK, Dey SK (1989) Cell type-specific localization of c-myc protein in the mouse uterus: modulation by steroid hormones and analysis of the perimplantation period. Endocrinology 125: 1683-1690.
15. Tan J, Paria BC, Dey SK, Das SK (1999) Differential uterine expression of estrogen and progesterone receptors correlates with uterine preparation for implantation and decidualization in the mouse. Endocrinology 140: 5310-5321.
16. Hewitt SC, Deroo BJ, Hansen K, Collins J, Grissom S, et al. (2003) Estrogen receptor-dependent genomic responses in the uterus mirror the biphasic physiological response to estrogen. Mol Endocrinol 17: 2070-2083.
17. Hewitt SC, Collins J, Grissom S, Deroo B, Korach KS (2005) Global uterine genomics in vivo: microarray evaluation of the estrogen receptor-alpha-growth factor cross-talk mechanism. Mol Endocrinol 19: 657-668.
18. Moggs JG, Tinwell H, Spurrell T, Chang HS, Pate I, et al. (2004) Phenotypic anchoring of gene expression changes during estrogen-induced uterine growth. Environ Health Perspect 112: 1589-1606.
19. Watanabe H, Suzuki A, Kobayashi M, Takahashi E, Itohato M, et al. (2003) Analysis of temporal changes in the expression of estrogen-regulated genes in the uterus. J Mol Endocrinol 30: 347-358.
20. Ivanga M, Labrie Y, Calvo E, Belleau P, Martel C, et al. (2007) Temporal analysis of E2 transcriptional induction of PTP and MPK and downregulation of IGF-I pathway key components in the mouse uterus. Physiol Genomics 29: 13-23.
21. Sato T, Okamura H, Ohta Y, Hayashi S, Takamatsu Y, et al. (1992) Estrogen receptor expression in the genital tract of female mice treated neonatally with diethylstilbestrol. In Vivo 6: 151-156.
22. Ohta Y, Sato T, Iuchi T (1993) Development and mitotic activity of the metrial gland in rat uterus during mid-pregnancy. In Vivo 7: 121-126.
23. Graham JD, Clarke CL (1997) Physiological action of progesterone in target tissues. Endocr Rev 18: 502-519.
24. Mowa CN, Iwanaga T (2000) Developmental changes of the oestrogen receptor-alpha and -beta mRNAs in the female reproductive organ of the rat— an analysis by in situ hybridization. J Endocrinol 167: 363-369.
25. Shughrue PJ, Lane MV, Scrimo PJ, Merchenthaler I (1998) Comparative distribution of estrogen receptor-alpha (ER-alpha) and beta (ER-beta) mRNA in the rat pituitary, gonad, and reproductive tract. Steroids 63: 498-504.
26. Wang H, Masironi B, Eriksson H, Sahlin L (1999) A comparative study of estrogen receptors alpha and beta in the rat uterus. Biol Reprod 61: 855-964.
27. Pelletier G, Labrie C, Labrie F (2000) Localization of oestrogen receptor alpha, oestrogen receptor beta and androgen receptors in the rat reproductive organs. J Endocrinol 165: 359-370.
28. Pelletier G, Luu-The V, Li S, Labrie F (2004) Localization and estrogenic regulation of androgen receptor mRNA expression in the mouse uterus and vagina. J Endocrinol 180: 77-85.
29. Hirai M, Hirata S, Osada T, Hagiura K, Kato J (1994) Androgen receptor mRNA in the rat ovary and uterus. J Steroid Biochem Mol Biol 49: 1-7.
30. Kimura N, Mizokami A, Oonuma T, Nasano H, Nagura H (1993) Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffin-embedded human tissues. J Histochem Cytochem 41: 671-678.
31. Blasberg ME, Robinson S, Henderson LP, Clark AS (1998) Inhibition of
estrogen-induced sexual receptivity by androgens: role of the androgen receptor. Horm Behav 34: 283-293.

32. Panet-Raymond V, Gottlieb B, Beitel LK, Pinsky L, Trifiro MA (2000) Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol 167: 139-150.

33. Cárdenas H, Pope WF (2004) Attenuation of estrogenic effects by dihydrotestosterone in the pig uterus is associated with downregulation of the estrogen receptors. Biol Reprod 70: 297-302.

34. Papapostantionou AD, Umbrell TH, Goering PL, Brown KM (2002) Effects of 17 alpha-methyltestosterone on uterine morphology and heat shock protein expression are mediated through estrogen and androgen receptors. J Steroid Biochem Mol Biol 82: 305-314.

35. Cunha GR, Cooke PS, Kurita T (2004) Role of stromal-epithelial interactions in hormonal responses. Arch Histol Cytol 67: 417-434.

36. American Cancer Society (2009) Cancer Reference Information. Atlanta: American Cancer Society What is Endometrial Cancer?

37. Hoffman B, Lieberman DA (2009) Gadd45 modulation of intrinsic and extrinsic stress responses in myeloid cells. J Cell Physiol 218: 26-31.

38. Zhang W, Bae I, Krishnaraju K, Azam N, Fan W, et al. (1999) CR6: A third member in the MyD118 and Gadd45 gene family which functions in negative growth control. Oncogene 18: 4899-4907.

39. Luu-The V, Paquet N, Calvo E, Cumps J (2005) Improved real-time RT-PCR method for high-throughput measurements using second derivative calculation and double correction. Biotechniques 38: 287-293.

40. Pelletier G, Dupont E, Simard J, Luu-The V, Belanger A, et al. (1992) Ontogeny and subcellular localization of 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) in the human and rat adrenal, ovary and testis. J Steroid Biochem Mol Biol 43: 451-467.

41. Nishida M, Kasahara K, Kaneko M, Iwasaki H, Hayashi K (1985) Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Nihon Sanka Fujinka Gakkai Zasshi 37: 1103-1111.

42. Dümberger H, Kratuchwlik K (1980) Specificity of tissue interaction and origin of mesenchymal cells in the androgen response of the embryonic mammary gland. Cell 19: 465-471.

43. Cooke PS, Buchanan DL, Lubahn DB, Cunha GR (1998) Mechanism of estrogen action: lessons from the estrogen receptor-alpha knockout mouse. Biol Reprod 59: 470-475.

44. Cuhna GR, Donjacak AY, Hayward SW (1998) Reciprocal mesenchymal-epithelial interactions in development of the male urogenital tract. Reproductive and developmental toxicology, Marcelll Dekker Inc.

45. Taylor WR, Stark GR (2001) Regulation of the G2/M transition by p53. Oncogene 20: 1803-1815.

46. Lee MS, Ogg S, Xu M, Parker LL, Donoghue DJ, et al. (1992) cdc25+ encodes a protein phosphatase that dephosphorylates p34cdc2. Mol Biol Cell 3: 73-84.

47. Jiang F, Wang Z (2004) Gadd45gamma is androgen-responsive and growth-inhibitory in prostate cancer cells. Mol Cell Endocrinol 213: 121-129.

48. Gadd SL, Hobbs G, Miller MR (2002) Aetamotoxin-induced proliferation of estrogen-responsive breast cancer cells is associated with increases in c-myc RNA expression and NF-kappaB activity. Toxicol Sci 66: 233-243.

49. Thompson CJ, Tann NN, Joyce JM, Leav I, Ho SM (2002) Gene expression profiling of testostere and estradiol-17 beta-induced prostatic dysplasia in Noble rats and response to the antestosterone ICI 192,760. Endocrinology 143: 2093-2105.

50. Xiao G, Chicas A, Olivier M, Taya Y, Tyagi S, et al. (2000) A DNA damage signal is required for p53 to activate gadd45. Cancer Res 60: 1711-1719.

51. Takahashi S, Saito S, Ohtani N, Sakai T (2001) Involvement of the Oct-1 regulatory element of the gadd45 promoter in the p53-independent response to ultraviolet irradiation. Cancer Res 61: 1187-1195.

52. Wan Y, Wang Z, Shaop X, Xu Y, Voorhees J, et al. (2000) UV-induced expression of GADD45 is mediated by an oxidant sensitive pathway in cultured human keratinocytes and in human skin in vivo. Int J Mol Med 6: 683-688.

53. Zhuang YH, Sarca D, Weisz A, Altucci L, Cicatiello L, et al. (2001) Cell type-specific induction of cyclin D and cyclin-dependent kinase inhibitor p27kip1 expression by estrogen in rat endometrium. J Steroid Biochem Mol Biol 78: 193-199.

54. Landesman Y, Brindig F, Milne DD, Meek DW (1997) Modifications of p53 protein and accumulation of p21 and gadd45 mRNA in TGF-b1 growth inhibited cells. Cell Signal 9: 291-298.

55. Balliet AG, Hollander MC, Fornace AJ Jr, Hoffman B, Lieberman DA (2003) Comparative analysis of the genetic structure and chromosomal mapping of the murine Gadd45/Cr6 gene. DNA Cell Biol 22: 457-468.

56. Skog S, He Q, Khoshnoosh R, Fernandez T, Rutvist LE (2004) Genes related to growth regulation, DNA repair and apoptosis in an oestrogen receptor-negative (MDA-231) versus an oestrogen receptor-positive (MCF-7) breast tumour cell line. Tumor Biol 25: 41-47.

57. Sutherland RL, Musgrove EA (2004) Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 9: 95-104.

58. Morgan DO (1995) Principles of CDK regulation. Nature 374: 131-134.

59. Jackman MR, Pines JN (1997) Cyclins and the G2/M transition. Cancer Surv 29: 47-73.

60. Pines J (1999) Multidimensional control of the cell cycle. Nat Cell Biol 1: E73-79.

61. Parker LL, Altherton-Fessler S, Lee MS, Ogg S, Falk JL, et al. (1991) Cyclin promotes the tyrosine phosphorylation of p34cdc2 in a wee1-dependent manner. EMBO J 10: 1255-1263.

62. Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, et al. (2002) Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J Clin Endocrinol Metab 87: 1262-1267.

63. Michalides R, van Tinteren H, Balkenende A, Vermorken JB, Benraadt J, et al. (2002) Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer 86: 402-408.

64. Tsuda H, Hashiguchi Y, Inoue T, Yamamoto K (2003) Alteration of G2 cell cycle regulators occurs during carcinogenesis of the endometrium. Oncology 65: 159-166.

65. Milde-Langsosch K, Bamberger AM, Goemann C, Rössig E, Rick G, et al. (2001) Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. J Cancer Res Clin Oncol 127: 537-544.

66. Kallakury BV, Ambros RA, Hayner-Buchan AM, Sheehan CE, Mafetano JH, et al. (1998) Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometroid subtypes. Int J Gynecol Pathol 17: 320-326.

67. Kulper GP, Carlson B, Grandien K, Enmark E, Häggblad J, et al. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138: 863-870.

68. Omoto Y, Lathe R, Warner M, Gustafsson JA (2005) Early onset of puberty and early ovarian failure in CYP7B1 knockout mice. Proc Natl Acad Sci U S A 102: 2814-2819.

69. Sikora MJ, Cordero KE, Larios JM, Johnson MD, Lippman ME, et al. (2009) The androgen metabolite Salpa-androstan-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. Breast Cancer Res Treat 115: 289-296.

70. Masamura S, Santner SJ, Hetjan DF, Santen RJ (1995) Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 80: 2918-2925.

71. Jeng MH, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D, et al. (1998) Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 139: 4164-4174.

72. Curtis SW, Washburn T, Sewart C, DiAugustine R, Lindzey J, et al. (1996) Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. Proc Natl Acad Sci U S A 93: 12626-12630.

73. Cloke B, Christian M (2011) The role of androgens and the androgen receptor in cycling endometrium. Mol Cell Endocrinol .
74. Appara KB, Lovely LP, Gui Y, Lininger RA, Lessey BA (2002) Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biol Reprod 66: 297-304.

75. Lovely LP, Appa Rao KB, Gui Y, Lessey BA (2000) Characterization of androgen receptors in a well-differentiated endometrial adenocarcinoma cell line (Ishikawa). J Steroid Biochem Mol Biol 74: 235-241.

76. Kalantaridou SN, Davis SR, Nelson LM (1998) Premature ovarian failure. Endocrinol Metab Clin North Am 27: 989-1006.

77. Kang Z, Pirskanen A, Jänne OA, Palvimo JJ (2002) Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem 277: 48366-48371.